Introduction to the Regeneron Class Action Lawsuit
- The Regeneron class action lawsuit seeks to represent purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”).
- Captioned Cheatham v. Regeneron Pharmaceuticals, Inc., No. 26-cv-06026 (S.D.N.Y.), the Regeneron class action lawsuit charges Regeneron and certain of Regeneron’s top executives with violations of the Securities Exchange Act of 1934.
- If you suffered substantial losses and wish to serve as lead plaintiff of the Regeneron class action lawsuit or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].
- Lead plaintiff motions for the Regeneron class action lawsuit must be filed with the court no later than September 8, 2026.
Read on for answers to the eight most frequently asked questions from investors.

1. What Is a Notice in a Class Action?
- A notice in a class action refers to the formal communication sent to potential class members informing them about the lawsuit and their rights to participate in it.
- This notice is a crucial part of the class action process as it ensures that all individuals who may be affected by the outcome of the Regeneron class action lawsuit are aware of their rights and can choose whether to opt-in or opt-out of the class.
- The notice typically contains information about the nature of the Regeneron class action lawsuit, the claims being made, and the potential benefits or risks associated with participation. It also provides instructions on how to file a claim or request exclusion from the class.
- Overall, the notice serves to promote transparency and fairness in the class action process by ensuring that all affected individuals have an opportunity to exercise their legal rights.
2. How Do I Ge Get Involved in the Regeneron class action lawsuit?
Regeneron class action lawsuit: Multiple shareholder class action lawsuits have been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), alleging that the company made misleading statements to investors about its Phase III Fianlimab-Libtayo clinical trial for advanced melanoma
The lawsuits state that Regeneron concealed flaws in the trial’s preliminary statistical assumptions and failed to disclose that the active treatment arm was not showing meaningful clinical differentiation over standard therapies. This ultimately led the trial to miss its primary endpoint—meaning the drug did not work as well as the company’s statements previously implied. The lawsuits allege that these mischaracterizations artificially inflated Regeneron’s stock price, which dropped sharply when the true results were revealed in mid-2026.
Key Case Information on the Regeneron Class Action Lawsuit
- Class Period: Investors who purchased or acquired Regeneron securities between August 1, 2025, and May 15, 2026, are eligible to participate.
- Lead Plaintiff Deadline: If you suffered financial losses during this time, you have until September 14, 2026, to ask the court to appoint you as lead plaintiff.
- What’s Next: Being a “lead plaintiff” means you represent the broader class of investors, but anyone who bought stock during the class period may be eligible to recover damages if the class wins or settles. Investors who choose not to seek lead plaintiff status can still participate as an absent class member without filing extra paperwork.
If you invested in Regeneron and experienced losses, you can learn about your legal rights or join the active investigations through several investor-rights law firms representing shareholders on a contingency basis (meaning you only pay attorney fees if you receive a recovery):
What Investors Can Do
If you wish to serve as lead plaintiff of the Regeneron class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].(24/7/365).

